Short Interest in XBiotech Inc. (XBIT) Drops By 2.2%

XBiotech Inc. (NASDAQ:XBIT) was the target of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 6,021,175 shares, a decrease of 2.2% from the November 15th total of 6,158,708 shares. Based on an average daily volume of 67,965 shares, the short-interest ratio is presently 88.6 days. Currently, 38.1% of the shares of the company are sold short.

XBiotech (NASDAQ:XBIT) opened at $4.19 on Thursday. XBiotech has a twelve month low of $2.77 and a twelve month high of $20.18.

Several institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its holdings in shares of XBiotech by 2.6% in the second quarter. Bank of New York Mellon Corp now owns 73,451 shares of the biopharmaceutical company’s stock worth $345,000 after acquiring an additional 1,883 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in shares of XBiotech by 6.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 64,203 shares of the biopharmaceutical company’s stock worth $1,059,000 after acquiring an additional 3,762 shares during the period. Teachers Advisors LLC boosted its holdings in shares of XBiotech by 12.9% in the second quarter. Teachers Advisors LLC now owns 36,031 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 4,116 shares during the period. Northern Trust Corp boosted its holdings in shares of XBiotech by 2.6% in the second quarter. Northern Trust Corp now owns 236,030 shares of the biopharmaceutical company’s stock worth $1,109,000 after acquiring an additional 6,051 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of XBiotech by 4.9% in the first quarter. Geode Capital Management LLC now owns 152,318 shares of the biopharmaceutical company’s stock worth $2,511,000 after acquiring an additional 7,066 shares during the period. 10.96% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Short Interest in XBiotech Inc. (XBIT) Drops By 2.2%” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://sportsperspectives.com/2017/12/21/short-interest-in-xbiotech-inc-xbit-drops-by-2-2.html.

XBiotech Company Profile

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply